Wednesday, September 19, 2007

Anticancer drug Tarceva received Patent Term Extension

OSI Pharmaceuticals Inc. has received a patent term extension for the US Pat. 5,747,498 (the ‘498 patent) covering anticancer drug Tarceva, generically known as erlotinib indicated for second-line advanced Non-Small Cell Lung Cancer (NSCLC) and for combination therapy for first-line advanced pancreatic cancer. The term of the ‘498 patent is extended by 1,251 days under 35 USC § 156, extending expiration date from June 06, 2015 to November 08, 2018. OSI has already received Supplementary Protection Certificates (SPCs) for Tarceva extending exclusivity to March 2020 in 14 Contracting States including France, Germany, Italy, Switzerland and the United Kingdom.

No comments:

Post a Comment